Key facts
- It has raised $500K; the latest was Early Stage VC ($500K) in Aug 2025.
- Notable investors include Brandon Capital, Booster Innovation Fund.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Cadmus Animal Health
- ·The full record, as it builds
Funding rounds
No funding rounds for Cadmus Animal Health are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cadmus Animal Health
Developer of an immunotherapeutic drug designed to treat chronic periodontal disease caused by the Porphyromonas bacterium in companion animals. The company offers a targeted treatment approach, enabling veterinarians to address the underlying cause of periodontal disease, improving the oral health of pets.
- Sector
- Business Products and Services (B2B)
- HQ
- Auckland, New Zealand
- Founded
- 2021
- Website
- cadmusah.com/
- Ownership
- Privately Held (backing)
Cadmus Animal Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cadmus Animal Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cadmus Animal Health in its N-PORT filings yet. We sweep new filings monthly.